EVP and President, Clinical Diagnostics Group

Client: Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Anette Engelhardt will join the company as its new Executive Vice President and President of the Clinical Diagnostics Group, effective June 10, 2024.

Ms. Engelhardt joins Bio-Rad from Cepheid, a wholly owned subsidiary of Danaher Corporation and a leading global molecular diagnostics company. While at Cepheid, Ms. Engelhardt was Senior Vice President and General Manager overseeing the emerging growth opportunities business, as well as Senior Vice President of global research and development, strategy, product management and marketing functions supporting the company’s extensive product portfolio.

Prior to Cepheid, Ms. Engelhardt held several senior positions at bioMerieux Inc., a global leader in in vitro diagnostics, including Senior Vice President of the company’s new technologies franchise and microbiology business unit. In these roles, she was responsible for developing and implementing product and market strategies for bioMerieux’s range of microbiology-related reagents, instruments, and services, as well as leveraging and commercializing new technologies. Ms. Engelhardt’s career also includes tenure as CEO of privately held AB BIODISK, where she managed the in vitro diagnostics company’s post-acquisition integration into bioMerieux. She began her career as a process engineer at AB BIODISK and holds a combined Master of Science and Bachelor of Science degree in Chemical Engineering and Polymer Technology from the Royal Institute of Technology in Stockholm, Sweden.

“We are very pleased to welcome Anette Engelhardt as President of our Clinical Diagnostics Group,” stated Andy Last, Bio-Rad’s Executive Vice President and Chief Operating Officer. “Anette brings to Bio-Rad extensive operational experience and a successful track record in developing and commercializing novel diagnostics products across multiple markets. We are confident her expertise will help advance our clinical diagnostics strategy to extend Bio-Rad’s core diagnostics and develop new products and market entries for our clinical business.”